Format

Send to

Choose Destination
BMC Vet Res. 2018 Mar 2;14(1):64. doi: 10.1186/s12917-018-1386-3.

Systematic review of antiepileptic drugs' safety and effectiveness in feline epilepsy.

Author information

1
Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium. marios.charalambous@ugent.be.
2
Clinical Unit of Internal Medicine Small Animals, University of Veterinary Medicine, Vienna, Austria.
3
Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
4
Department of Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, Brookmans Park, UK.

Abstract

BACKGROUND:

Understanding the efficacy and safety profile of antiepileptic drugs (AEDs) in feline epilepsy is a crucial consideration for managing this important brain disease. However, there is a lack of information about the treatment of feline epilepsy and therefore a systematic review was constructed to assess current evidence for the AEDs' efficacy and tolerability in cats. The methods and materials of our former systematic reviews in canine epilepsy were mostly mirrored for the current systematic review in cats. Databases of PubMed, CAB Direct and Google scholar were searched to detect peer-reviewed studies reporting efficacy and/or adverse effects of AEDs in cats. The studies were assessed with regards to their quality of evidence, i.e. study design, study population, diagnostic criteria and overall risk of bias and the outcome measures reported, i.e. prevalence and 95% confidence interval of the successful and affected population in each study and in total.

RESULTS:

Forty studies describing clinical outcomes of AEDs' efficacy and safety were included. Only two studies were classified as "blinded randomised controlled trials". The majority of the studies offered high overall risk of bias and described low feline populations with unclear diagnostic criteria and short treatment or follow-up periods. Individual AED assessments of efficacy and safety profile showed that phenobarbital might currently be considered as the first choice AED followed by levetiracetam and imepitoin. Only imepitoin's safety profile was supported by strong level of evidence. Imepitoin's efficacy as well as remaining AEDs' efficacy and safety profile were supported by weak level of evidence.

CONCLUSIONS:

This systematic review reflects an evidence-based assessment of the published data on the AEDs' efficacy and safety for feline epilepsy. Currently, phenobarbital is likely to be the first-line for feline epileptic patients followed by levetiracetam and imepitoin. It is essential that clinicians evaluate both AEDs' effectiveness and tolerability before tailoring AED to the individual patient. Further studies in feline epilepsy treatment are by far crucial in order to establish definite guidelines for AEDs' efficacy and safety.

KEYWORDS:

adverse effects; antiepileptic drugs; comprehensive review; efficacy; epilepsy; feline

PMID:
29499762
PMCID:
PMC5834883
DOI:
10.1186/s12917-018-1386-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center